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Nomogram to Diagnose Familial Combined Hyperlipidemia
on the Basis of Results of a 5-Year Follow-Up Study
Mario J. Veerkamp, MD; Jacqueline de Graaf, MD, PhD; Jan C.M. Hendriks, PhD;
Pierre N.M. Demacker, PhD; Anton F.H. Stalenhoef, MD, PhD
Background—Familial combined hyperlipidemia (FCH) is traditionally diagnosed by total plasma cholesterol and/or
triglyceride levels above the 90th percentile adjusted for age and gender. In a recent study, we showed that the diagnosis
of FCH on the basis of these diagnostic criteria was inconsistent in 26% of the subjects over a 5-year period. This result
emphasizes the need for reevaluation of the diagnostic criteria for FCH.
Methods and Results—A total of 32 families (299 subjects) were studied in 1994 and 1999. A subject was defined “truly”
FCH when diagnosed FCH in 1994 and/or 1999 on the basis of traditional plasma lipid criteria. Additional lipid and
lipoprotein parameters, including apolipoprotein B (apoB) and small, dense LDL, were measured at both time points.
In total, 121 subjects (40%) were defined as truly FCH. Multivariate analysis revealed that absolute apoB values
combined with triglyceride and total cholesterol levels adjusted for age and gender best predicted truly FCH. A
nomogram including these parameters is provided to simply and accurately calculate the probability to be affected by
FCH. Furthermore, it is shown that when percentiles of triglyceride and total cholesterol adjusted for age and gender
are not available in a population, the definition of FCH can be established on the basis of hypertriglyceridemia
(1.5 mmol/L) and hyper-apoB (1200 mg/L).
Conclusions—The diagnosis of FCH is best predicted by absolute apoB levels combined with triglyceride and total
cholesterol levels adjusted for age and gender and can accurately be calculated by a nomogram. This definition is also
a good predictor of cardiovascular risk in FCH. (Circulation. 2004;109:2980-2985.)
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Familial combined hyperlipidemia (FCH) was first de-scribed in 1973 as a common familial disorder charac-
terized by multiple lipoprotein phenotypes and increased risk
of premature cardiovascular disease (CVD).1 In the 30 years
since it was described, the genetic basis for FCH has
remained elusive; indeed, even the mode of inheritance
remains controversial. Obviously, no genetic hypothesis can
be reliably tested when there is no consistent phenotype to
establish the diagnosis of FCH.
FCH is characterized by several phenotypes, including
increased total cholesterol (TC), increased triglycerides (TG),
decreased HDL cholesterol (HDL-C), increased apolipopro-
tein B (apoB), and the presence of small, dense LDL. Not all
research groups use the same criteria to establish the diagno-
sis of FCH.2,3 There are even more fundamental problems.
Among the most important is that the lipid phenotype can
vary substantially within any individual. Recently, we
showed in a 5-year follow-up study (1994 to 1999) of 32
families that the diagnosis of FCH on the basis of plasma TC
and/or TG level 90th percentile (pTC or pTG 90th)
adjusted for age and gender is consistent in only 74% of the
subjects.4 Most importantly, 26% of the subjects with FCH in
1994 had a sporadic normolipidemic pattern in 1999 defined by
pTC and pTG levels90th corrected for age and gender. Thus,
the classic lipid phenotypes are variable not only among family
members but also within individuals. This has previously been
suspected but has now been convincingly demonstrated by our
data and by recent data of McNeely et al.5
Although the genetic origin of FCH has remained obscure,
much has been learned about its pathophysiology. The
characteristic abnormality is an increased production of
VLDL with or without impaired clearance of TG-rich li-
poproteins in most patients6 that results in the generation of
increased numbers of small, dense LDL particles. This
suggests that just as a variable lipid phenotype is the hallmark
of FCH within a family, an elevated plasma apoB might be
the common hallmark of FCH within an individual. Indeed,
this was a principal finding of our previous study,4 which
demonstrated that subjects affected FCH in 1994 and/or 1999
had significantly higher apoB levels and an increased amount
of small, dense LDL compared with nonaffected subjects,
even when they presented a normolipidemic phenotype.
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Together with less variability in time, measurements of apoB
and small, dense LDL in plasma could potentially lead to
more consistent diagnostic criteria for FCH with a better
discriminant power to separate affected from nonaffected
relatives compared with TC and TG levels alone.
The objective of the present study is to evaluate several
diagnostic features of FCH and to provide a nomogram that
can simply and accurately predict FCH in clinical practice.
Methods
Study Population
The study population consisted of kindreds and probands of families
with known FCH who were recruited in 1994 and followed up in
1999 as recently described elsewhere.4 At both time points of
investigation, all subjects completed a questionnaire about medical
history, especially cardiovascular status. Body mass index was
determined in all subjects. After withdrawal of lipid-lowering med-
ication for 4 weeks and after an overnight fast, venous blood was
drawn by venipuncture. Subjects were classified as affected by FCH
when plasma pTC and/or pTG 90th on the basis of the PROCAM
study.7 These percentiles are adjusted for age and gender. Nonaf-
fected relatives were defined by TC and TG levels 90th percentile
(pTC and pTG 90th). The ethics committee of the University
Medical Center Nijmegen approved the study protocol.
In total, 32 families, including 299 subjects, were studied in both
1994 and 1999. In 1994, 93 of the 299 subjects (31%) were affected
by FCH. The diagnosis of FCH in 1999 was consistent with the
diagnosis in 1994 in only 69 of the 93 subjects (74%). Most
importantly, however, 24 subjects (26%) with FCH in 1994 showed
a normolipidemic pattern in 1999, and 28 (14%) of the normolipi-
demic subjects, ie, pTC and pTG 90th, in 1994 were affected in
1999. Of the 206 nonaffected relatives in 1994, 178 (86%) remained
nonaffected in 1999.4 In the present study, we define all subjects who
were diagnosed with FCH in 1994 and/or 1999, on the basis of the
traditional lipid criteria (pTC and/or pTG 90th), as affected by
FCH. Thus, this definition also includes the subjects with FCH in
1994 who show a normolipidemic pattern in 1999 (Table 1). We
refer to these affected FCH subjects as “truly” FCH.
Plasma Lipid, Lipoprotein, and
Apolipoprotein Analyses
Plasma TC and TG concentrations were determined by enzymatic,
commercially available reagents (Boehringer-Mannheim, catalog
No. 237574, and Sera Pak, Miles, catalog No. 6639, respectively).
HDL-C was determined by the polyethylene glycol 6000 method.8
LDL cholesterol (LDL-C) was calculated by subtraction of VLDL
cholesterol and HDL-C from plasma TC. Total plasma apoB con-
centrations were determined by immunonephelometry.9 Coefficient
of variation estimates of the analytical and biological variation of
apoB in our laboratory were 7%.
LDL subfractions were separated by single spin density gradient
ultracentrifugation.10 Each individual LDL subfraction profile was
defined by a continuous variable K, as described in detail previous-
ly.11 A negative value (K0) reflects a more dense LDL subfraction
profile; a positive K value (K 0) indicates a more buoyant profile.
Statistical Analyses
The Mann-Whitney test was used to test differences at baseline
between truly FCH subjects and their unaffected relatives for
statistical significance in the case of quantitative variables; the
2-tailed Fisher’s exact test was used in the case of qualitative
variables.
Univariate logistic regression was used to evaluate the prognostic
ability of the variables separately to discriminate between truly FCH
subjects and their unaffected relatives. Because the apoB level, K
value, and TC and TG levels in particular were expected to be
nonlinearly related in the logistic model, reasonable cutoff values for
these variables to discriminate between truly FCH subjects and their
unaffected relatives were constructed. At this point, the condition of
equal “costs” of misclassification of cases and noncases was used. In
other words, the optimal cutoff value for a particular variable was
chosen so that the sum of the sensitivity and the specificity to
discriminate truly FCH subjects from their unaffected relatives was
maximal. Crude ORs with 95% CIs are presented.
Multivariate logistic regression analysis with selection procedures
was used to determine the variables that were sufficient and complete
to contribute independently to the prediction of truly FCH. Because
forward selection procedures do not identify other important vari-
ables, probability values for entry into the model were considered to
find close alternatives to the variables selected. Adjusted ORs with
95% CIs are presented. With the multivariable prognostic model, a
boundary value of the probability to be truly FCH, given the values
of the prognostic variables only, was constructed, again under the
condition of equal costs of misclassification of cases and noncases.
In case of a 2-variable prognostic model, a straight line dissociated
cases (ie, truly FCH with high probability) and noncases. In case of
a 3-variable prognostic model, a nomogram was constructed.
Finally, univariate logistic regression was used to evaluate the
prognostic ability of variables separately to identify patients with
CVD compared with normal subjects. Statistical analysis was per-
formed by using procedures available in SAS (software package
2000, SAS Institute Inc).
Results
In total, 32 families, or 299 subjects, were studied in both
1994 and 1999. One hundred twenty-one subjects were
defined as truly FCH on the basis of plasma pTC and/or pTG
90th adjusted for age and gender in 1994 and/or 1999
(Table 1). Thus, 40% of the study population was truly FCH,
whereas 31% in 1994 and 32% in 1999 were affected by
FCH. Table 2 shows the anthropometric measurements, lipid
and (apo) lipoprotein concentrations, and values of K, reflect-
ing LDL heterogeneity, in truly FCH subjects and nonaf-
fected relatives in 1994. Truly FCH subjects were signifi-
cantly older and had a higher body mass index than
normolipidemic relatives. As expected, among subjects with
FCH, CVD was more prevalent. By definition, the truly FCH
group had higher TC and TG concentrations. The truly FCH
group also exhibited significantly higher concentrations of
LDL-C and lower concentrations of HDL-C. Furthermore,
significantly higher levels of apoB and lower values of the
parameter K, reflecting small, dense LDL, were found in the
truly FCH group compared with unaffected relatives.
Crude ORs to predict truly FCH are given in Table 3. All
variables except gender contributed independently to the
diagnosis of truly FCH.
TABLE 1. Subjects in 32 Families Defined as Affected By FCH
or Normolipidemic Relatives in 1994 and 1999
1999, n (%)
1994 FCH NL Total
FCH 69 (74)* 24 (26)* 93 (31)
NL 28 (14)* 178 (86) 206 (69)
Total 97 (32) 202 (68) 299 (100)
NL indicates normolipidemic relatives defined by pTC and pTG 90th. FCH
was based on pTC and/or pTG levels 90th.
*Subjects classified as truly FCH defined by affected FCH based on pTC
and/or pTG 90th in 1994 and/or 1999. In total, 121 subjects (40%) of the
study population were defined as truly FCH.
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Receiver-operating curve analysis shows that the K value,
reflecting LDL heterogeneity, and apoB levels are nearly as
good at predicting truly FCH as the traditional lipid criteria,
including TC and TG levels. Next, the variables were
dichotomized by determining the optimal cutoff values of
apoB, TC, TG, and K for prediction of truly FCH (Table 4).
In our cohort, cutoff values of apoB 1200 mg/L, K
0.10, TG levels 1.5 mmol/L (pTG 6), and TC levels
6.0 mmol/L (pTC 7) were found.
To evaluate which (combination of) phenotype(s) best
predicted truly FCH, we included all the variables presented
in Table 3 in a multivariate logistic regression model. This
analysis revealed that the absolute apoB value in combination
with pTG and pTC best predicted truly FCH with an
R269%. pTG was the strongest independent predictor of
truly FCH (R258%); when percentiles are not available, TG
concentrations 1.5 mmol/L can be used to predict truly
FCH. When TG levels in percentiles were included in the
model, the K value did not provide additional information. In
the next step of the regression analysis, apoB was the second
most important predictor of FCH. Including apoB levels with
pTG in the model improved R2 to 68%. Finally, pTC
contributed significantly to truly FCH, although the R2 did not
increase substantially. The R2 (ie, the amount of variation) for
the combination of these 3 variables was 69%.
By logistic regression, the probability of classification of
affected FCH on the basis of absolute apoB values and pTG
and pTC was assessed at 60%. In Figure 1, the 2 most
informative variables in predicting truly FCH, including apoB
and pTG levels, are plotted for all individuals. The optimal
cutoff value to predict truly FCH on the basis of the
combination of absolute apoB with pTG is 0.52. The shaded
area indicates high probability of predicting truly FCH using
the observed apoB and pTG values. This figure shows that the
prediction area makes a fairly good distinction between truly
FCH subjects and nonaffected subjects.
Finally, a nomogram was constructed to calculate the
probability of affected by FCH (Figure 2). For each of the 3
variables (pTG, pTC, and absolute apoB levels), the corre-
sponding number of points is read from the scale below.
These are then summed to give a total point score, which can
be translated into a probability of being affected by FCH by
using the 2 scales at the bottom. The optimal cutoff point for
the probability of affected FCH was determined under the
condition of equal costs of misclassification according to
sensitivity and specificity. When having a probability of
60% the subject is defined as affected by FCH when at least
1 other family member also exhibits the FCH phenotype and
at least 1 individual in the family has premature CVD. For
example, a subject with a pTG of 7 (between 91% and 95%,
8 points), a pTC of 6 (between 76 %and 90%, 2.8 points), and
an apoB level of 1600 mg/L (4.3 points) will receive a total
of 15.1 points. The probability of being affected by FCH is
then 0.92. Thus, according to this test, this individual subject
(if a member of a FCH family) is being affected by FCH.
Diagnosis of FCH as a Predictor for CVD
In 1999, 41 subjects (14%) had a history of CVD. To define
the ability of the different FCH definitions to predict CVD,
sensitivity and specificity were determined. FCH diagnosis
based on traditional lipid criteria, including pTC and/or pTG
90th adjusted for age and gender, showed a sensitivity and
specificity to predict CVD of 45% and 27% respectively. The
proposed new FCH diagnosis based on pTG, pTC, and
absolute apoB had a sensitivity and specificity for CVD risk
prediction of 59% and 72%, respectively. In the literature, the
diagnosis of FCH has also recently been defined as hyper-TG
(TG 1.5 mmol/L) and hyper-apoB (apoB 1200 mg/L). In
our cohort, the diagnosis of FCH on the basis of these criteria
(hyper-TG plus hyper-apoB) had corresponding values of
sensitivity and specificity to predict FCH (64% and 72%,
respectively). Thus, both new definitions of FCH improved
CVD risk prediction compared with the FCH diagnosis based
on traditional lipid criteria.
TABLE 3. Crude ORs to Predict Truly FCH With Univariate
Logistic Regression
Independent Variables OR 95% CI R 2, % AUC, %
Gender (M vs F) 1.13 0.71–1.79 1 52
Age (y) 1.20 1.11–1.30 7 65
BMI (kg/m2) 1.41 1.29–1.55 31 79
TC absolute (mmol/L) 3.08 2.36–4.02 40 82
pTC 2.32 1.88–2.85 37 79
TC 6.0 mmol/L 7.19 4.29–12.07 25 73
TG absolute (mmol/L) 11.51 6.43–20.61 58 89
pTG 3.24 2.48–4.24 54 87
TG 1.5 mmol/L 15.19 8.53–27.03 41 80
ApoB absolute (per 100 mg/L) 1.76 1.54–2.01 49 86
ApoB 1200 mg/L 12.31 6.99–21.69 37 78
K value absolute (per 0.1) 0.60 0.51–0.69 27 78
K value 0.1 9.62 5.50–16.82 31 76
AUC indicates area under the curve as a measure of predictive discrimination
(eg, 50% is equivalent to random guessing and 100% is the perfect prediction);
BMI, body mass index.
TABLE 2. Anthropometric Measurements, Lipid and
(Apo)lipoprotein Concentrations, and Value of K in Truly FCH
Subjects and Normolipidemic Relatives in 1994
Truly FCH
(n121)
Normolipidemic Relatives
(n178)
Age, y 48 (19–73)* 34 (13–71)
BMI, kg/m2 26 (18–37)* 23 (15–35)
CVD, n (%) 18 (15)† 5 (3)
TC, mmol/L 6.9 (3.7–9.0)* 5.2 (2.4–7.5)
TG, mmol/L 2.4 (0.2–15.0)* 1.0 (0.3–2.9)
LDL-C, mmol/L 4.48 (1.67–6.63)* 3.47 (1.25–5.71)
HDL-C, mmol/L 0.98 (0.53–2.56)* 1.25 (0.55–2.47)
ApoB, mg/L 1374 (604–2640)* 914 (467–1640)
K value 0.23 (0.58–0.59)* 0.03 (0.48–0.41)
BMI indicates body mass index. Values are median (minimum-maximum).
Values of K 0 reflect small, dense LDL.
*P0.001, Mann-Whitney test, †P0.001, Fisher’s exact test.
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The predictive value of the nomogram for CVD analyzed
as a quantitative trait shows that the median probability of
being affected by FCH is 3.5 times higher in patients with
CVD (median, 0.71; 95% CI, 0.54 to 0.80) compared with
patients without CVD (median, 0.20; 95% CI, 0.28 to 0.38)
(P0.001, t test using angular transformed data).
Discussion
We propose a new definition of FCH based on absolute apoB
levels and TG and TC levels, both adjusted for age and
gender. A nomogram is provided to simply and reliably read
the probability to be affected by FCH in clinical practice
(Figure 2). This nomogram has been constructed using data
from our large FCH cohort including 299 subjects with 5-year
follow-up. This new definition of FCH also reflects increased
CVD risk in contrast to the traditional criteria of FCH.
Until now, different research groups used different defini-
tions of FCH.1–3 In a recent follow-up study, we showed that
for the diagnosis FCH, only plasma TC and TG levels
adjusted for age and gender are insufficient.4 Furthermore,
the FCH phenotype based on TC and/or TG levels alone is
physiologically incoherent.12 When the traditional lipid phe-
notype is variable and insufficient, accurate clinical diagnosis
in individual subjects is not possible. Equally important,
genetic characterization becomes problematic, and biologi-
cally correct hypotheses may be falsely rejected because of
inaccurate diagnosis. For all these reasons, it is necessary to
create unequivocal standardized diagnostic criteria of FCH.
The present study shows that absolute apoB levels combined
with pTG and pTC are most informative to predict FCH.
ApoB as a Diagnostic Feature of FCH
In our previous study, subjects with FCH had significantly
higher apoB concentrations compared with nonaffected rela-
tives, even when they had a sporadic normolipidemic pheno-
type.4 Additionally, in the follow-up study of McNeely et al,5
apoB levels were highest among individuals who were
consistently affected by FCH, intermediate among those who
switched phenotypes, and lowest among individuals who
were consistently normolipidemic. In addition, several other
studies have shown that apoB is an important phenotypic
measure in FCH.4,13–16 ApoB fits with the most important
pathophysiological feature of FCH, increased VLDL secre-
tion and impaired clearance of postprandial lipoproteins,
resulting in hypertriglyceridemia, elevated plasma apoB, and
small, dense LDL. Another practical advantage of including
apoB level as a new diagnostic criterion of FCH is diagnosing
FCH at a younger age. A number of studies have shown that
in teenaged children, apoB may be elevated, whereas lipids
are not.2,17 A limitation in using apoB as a diagnostic criterion
for FCH is the need for an apoB measurement standardized
according to the WHO-IFCC standardization program. ApoB
can be measured with the same precision and accuracy as the
lipoprotein lipids.18 All these data encourage the inclusion of
apoB in the phenotypic definition of FCH.
The present study shows in a large FCH cohort with 5-year
follow-up that the optimal cutoff point for apoB to predict
FCH is 1200 mg/L. Subjects with an apoB level 1200
TABLE 4. Optimal Cutoff Values With Receiver-Operating Curve Parameters for
ApoB, K, Absolute TG and TC, pTG, and pTC for Prediction of Truly FCH With
Univariate Logistic Regression Under the Condition of Equal Cost
of Misclassification
Cutoff Point Probability Maximum J Sensitivity Specificity
ApoB (mg/L) 1200 0.44 0.55 0.77 0.79
K value 0.10 0.40 0.51 0.77 0.74
TG (mmol/L) 1.5 0.35 0.59 0.81 0.78
TC (mmol/L) 6.0 0.42 0.46 0.70 0.75
pTG 6 0.58 0.61 0.77 0.84
pTC 7 0.74 0.51 0.51 1.00
Figure 1. Probability of classification of affected by truly FCH on
the basis of absolute apoB concentration and TG levels
adjusted for age and gender. Shaded area indicates probability
of truly FCH of 0.52 on the basis of absolute apoB concentra-
tion and TG levels adjusted for age and gender. This area was
optimal to discriminate those truly FCH from unaffected subjects
under condition of equal costs of misclassification. For ease of
presentation, unaffected subjects are shifted upward, truly FCH
subjects are shifted downward, and cutoff point of pTG (90th
percentile) is presented at 6.5. For pTG and pTC, 10% to 5%;
26% to 10%; 311% to 25%; 426% to 50%; 551% to
75%; 676% to 90%; 791% to 95%; 896% to 100%. 
indicates truly FCH subjects; , unaffected subjects.
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mg/L have an increased probability to be affected by FCH
(OR, 12.3; 95% CI, 6.99 to 21.69) compared with subjects
with an apoB level 1200 mg/L. The level of apoB 1200
mg/L has been suggested in previous studies. It corresponds
to roughly the 75th percentile in men (results of the Framing-
ham Offspring study),19 and subjects with apoB concentra-
tions 1200 mg/L were significantly more likely to have
CVD than subjects with apoB levels 1200 mg/L.20 Thus,
our data now show convincingly that the measurement of
apoB concentration is imperative for the diagnosis of FCH.
Small, Dense LDL and TG Levels as Diagnostic
Features of FCH
Small, dense LDL, reflected by the K parameter, is also an
important feature in FCH.16,21–23 We previously showed that
subjects with FCH had significantly lower levels of K,
reflecting atherogenic small, dense LDL, compared with
nonaffected relatives, even when they had a sporadic normo-
lipidemic phenotype.4 However, this was not shown in the
follow-up study of McNeely et al,5 maybe because different
methods were used to determine small, dense LDL. The
present study shows that the optimal cutoff point for K to
predict FCH is 0.10, reflecting small, dense LDL.
However, although small, dense LDL is an important
feature of FCH, it is of interest that in multivariate analysis,
K, reflecting LDL heterogeneity, did not provide additional
information in predicting FCH after inclusion of TG, which is
the most important predictor of truly FCH, most likely
because of the strong correlation between LDL heterogeneity
and TG levels (r0.68). Serum TG concentration has been
suggested to be the most important predictor of LDL size in
FCH patients.23 In both earlier studies9,24 and this study, we
have confirmed that plasma TG levels 1.5 mmol/L distin-
guish optimally between atherogenic small, dense LDL and a
large, buoyant LDL subfraction profile.
Hyper-TG and Hyper-ApoB as Diagnostic
Features of FCH
In an international forum on FCH in 2001, a proposal to
redefine FCH was made that was based on hyper-TG and
hyper-apoB.12 The cutoff points proposed were 1200 mg/L
for apoB and 1.5 mmol/L for plasma TG. The choice of
these cutoff points was tentative and based on the reports
mentioned earlier. We show here for the first time that cutoff
points of1200 mg/L for apoB and1.5 mmol/L for TG are
justified on the basis of our large FCH cohort with 5-year
follow-up.
Comparing the absolute apoB value combined with pTG
and pTC as diagnostic criteria for FCH with hyper-TG and
hyper-apoB reveals that the diagnosis based on these com-
bined values better predicted truly FCH (R269% versus
50%, respectively).
The disadvantage of using percentiles of lipid levels in the
definition of FCH is that these levels vary substantially across
the world and therefore will affect decisions on cutoff levels.
Lipid levels are changing, and up-to-date, accurate informa-
tion on lipid levels and threshold values is not available in
many populations. An advantage of using percentiles is the
Figure 2. Nomogram to calculate probability of being affected by FCH using absolute apoB and TG-TC values adjusted for both age
and gender. In each of 3 variables, points are calculated by reading from point scale. Total point score is then translated into probabil-
ity of affected FCH using 2 bottom scales. For example, subject with pTG between 91% and 95%, pTC between 76% and 90%, and
apoB level of 1600 mg/L will receive total of 15.1 points (ie, 82.84.3) according to 4 top lines. Probability of being affected by FCH
with total points of 15.1 is then 0.92, according to 2 bottom lines. This subject, therefore, is affected by FCH when also at least 1 other
family member exhibits the FCH phenotype and at least 1 individual in the family has premature CVD.
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correction for age and gender, but assignment of percentiles
still depends on the population.
To take into account the great interindividual variability in
apoB and TG levels, we recommend using apoB and TG
levels as quantitative traits instead of a dichotomy, ie, apoB
1200 mg/L and TG1.5 mmol/L. Much information is lost
because we do not know whether an individual is close to or
far from the threshold. Moreover, where family data are used,
quantitative traits of relatives are often more informative than
their affected status. As a clinical tool, a nomogram was
constructed to simply and reliably calculate the probability of
FCH in an individual subject on the basis of quantitative
apoB, pTG, and pTC values. In case pTC and pTG are not
available, we show that it is acceptable to define FCH by TG
levels 1.5 mmol/L and apoB values 1200 mg/L.
Finally, we found that our new definition of FCH is of
value in predicting CVD risk. Subjects fulfilling the new FCH
definition have an increased risk of CVD (OR, 3.8; 95% CI,
7.0 to 21.7). Subjects fulfilling the definition of hyper-TG and
hyper-apoB have a comparable OR (4.6; 95% CI, 2.3 to 9.2)
in contrast to the diagnosis of FCH based on traditional lipid
criteria (pTC and/or pTG 90th), which had an OR of only
0.3 (95% CI, 0.2 to 0.6). Similar results have been reported
for intima-media thickness, a surrogate end point of CVD.25
Using the proposed new diagnostic criteria included in a
nomogram will make it easier to identify patients and test
relatives to diagnose FCH. Still, the diagnostic phenotype has
to be present in 1 family member, and 1 individual in the
family must have premature CVD to diagnose FCH. Confir-
mation of the relevance of this new definition of FCH in other
large FCH cohorts is warranted to confirm the unequivocal
diagnostic criteria for FCH.
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